SolarEdge Stock Jumps as Bigger Battery Bet Puts Its Turnaround to the Test
23 April 2026
2 mins read

SolarEdge Stock Jumps as Bigger Battery Bet Puts Its Turnaround to the Test

NEW YORK, April 23, 2026, 17:03 EDT

SolarEdge Technologies Inc surged over 11% Thursday, closing at $47.36. That move bumped the solar equipment maker’s valuation to around $2.8 billion, outstripping gains in Enphase Energy, First Solar, and Sunrun—those rose just 2% to 4%. Late-day market data put SolarEdge’s trading volume above 5.6 million shares.

This shift is significant for SolarEdge, which aims to prove it can turn a sector slump into an actual rebound. Revenue for 2025 landed at $1.18 billion, marking a 31% jump. Even so, a GAAP net loss of $405.4 million still weighed on the bottom line. Free cash flow hit $76.9 million—money available after capital expenses. Back in February, Chief Executive Shuki Nir declared the company was “shifting decisively to offense.” SolarEdge Technologies, Inc.

SolarEdge’s newest entry, the CSS-OD 197, brings a 197 kilowatt-hour battery system to the commercial and industrial market, with kilowatt-hours indicating stored energy. The company is rolling out orders now across Europe and Asia. Each system combines a 197 kWh cabinet and up to two 50-kilowatt battery inverters, with the option to expand—sites can build out to 1 megawatt of power and as much as 4 megawatt-hours of storage. “The response to the first CSS-OD was extremely encouraging,” said Naama Ohana, who heads SolarEdge’s C&I division. SolarEdge Technologies, Inc.

The battery targets a few things: self-consumption, peak shaving, tariff optimization, and capping import-export. Put simply, it allows businesses to stash energy from solar panels and tap into that stored power when grid rates jump, or if a facility needs to trim its peak grid usage.

Europe takes the spotlight in the strategy. “We’re represented and installing batteries across most relevant regions in Europe,” Jacques van der Bijl, SolarEdge’s director of C&I products in Europe, told ESS News, listing Germany, Austria, Switzerland, the Netherlands, Poland and France. He pointed out that bigger sites have been stacking multiples of the older 102 kWh system—so a larger cabinet simply makes more sense on costs. Energy Storage

Wall Street’s attitude remains skeptical. According to MarketBeat, SolarEdge has just one buy, with 17 analysts holding and seven recommending a sell. The consensus? “Reduce.” Their average price target sits at $29.90—a sharp discount to Thursday’s close. MarketBeat

SolarEdge brought a handful of governance items to shareholders this week. According to a proxy filed Thursday, investors are set to weigh in on June 3 in New York: seven nominees for the board, ratifying the auditor, a say-on-pay proposal, and a charter change targeting liability limits for some officers.

The battery debut hardly erases the bear scenario. In its annual report, SolarEdge flagged a familiar lineup of risks: profitability ahead, solar rivals turning up the heat, shifting tax and tariff rules, erratic demand, and the threat of turbulence linked to Israel. Elsewhere, market analysts cautioned that heavy competition in commercial storage could squeeze margins—especially if SolarEdge ends up cutting prices to secure deals.

This next clear signal? It’s not tied to the product reveal—it’s orders that matter. Investors are watching to see if storage sales from Europe and Asia feed into revenue, margins, and working capital, rather than just pushing the share price higher.

Stock Market Today

  • Siren Exits Ascendis Pharma with $50 Million Sale Amid Strong Quarterly Performance
    May 14, 2026, 3:43 PM EDT. On May 14, 2026, investment fund Siren sold its entire stake in Ascendis Pharma A/S, offloading 235,862 shares in a $52.87 million transaction based on first-quarter average prices. The divestment reduced Siren's position by approximately $50.3 million, including sales and market price effects. Despite this exit, Ascendis shares have risen 50% over the past year, outperforming the S&P 500 by 24 percentage points. The Danish biopharma company recently reported robust Q1 results, with revenue doubling to 247 million euros driven by sales of YORVIPATH and SKYTROFA, and recorded a net profit boosted by a deferred tax asset. Ascendis focuses on rare endocrine and pediatric diseases using its TransCon technology. Siren's sale does not signal a negative outlook amid Ascendis' strong momentum and expanding rare disease patient base.

Latest articles

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

14 May 2026
REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

14 May 2026
Digi Power X shares fell 14% to $7.28 in heavy trading Thursday ahead of its first-quarter results and operations update due May 15. Investors are focused on its $1.1 billion, 10-year AI data-center deal with Cerebras and a $19.6 million SubQ AI GPU rental contract launching Friday. The company also expanded its at-the-market share-sale program to $175 million.
Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

14 May 2026
Smart Powerr shares jumped to 78.83 cents, up nearly 59 cents from the previous close, after hitting 90.37 cents intraday. The surge followed news that Nasdaq warned the company over its sub-$1 share price and possible suspension. Trading volume reached about 395 million shares. The company said a hearing request would delay any suspension but gave no assurance of keeping its Nasdaq listing.
Tempus AI Stock Falls After USC Deal, Putting Its Cancer Data Push To The Test
Previous Story

Tempus AI Stock Falls After USC Deal, Putting Its Cancer Data Push To The Test

Expedia Stock Sinks After Former Snap CFO Derek Andersen Takes Finance Job Before Earnings
Next Story

Expedia Stock Sinks After Former Snap CFO Derek Andersen Takes Finance Job Before Earnings

Go toTop